Immunicum AB - ESG Rating & Company Profile powered by AI
The assessment of Immunicum AB employs intelligence from across the web as well as from public filings by Immunicum AB. The webpage displays a zero-cost Environmental, Social and Governance report for Immunicum AB. Comprehensive ESG assessment of Immunicum AB can be accessed by signing in.
Immunicum AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.9; made up of an environmental score of 5.3, social score of 6.4 and governance score of 6.0.
5.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 498 | Redx Pharma PLC | 6.0 | High |
| 498 | Vimta Labs Ltd | 6.0 | High |
| 521 | Immunicum AB | 5.9 | High |
| 521 | Cellink AB | 5.9 | High |
| 521 | Celon Pharma SA | 5.9 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Immunicum AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Immunicum AB disclose current and historical energy intensity?
Sign up for free to unlockDoes Immunicum AB report the average age of the workforce?
Sign up for free to unlockDoes Immunicum AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Immunicum AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes Immunicum AB disclose cybersecurity risks?
Sign up for free to unlockDoes Immunicum AB offer flexible work?
Sign up for free to unlockDoes Immunicum AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Immunicum AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Immunicum AB conduct supply chain audits?
Sign up for free to unlockDoes Immunicum AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Immunicum AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes Immunicum AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes Immunicum AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Immunicum AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Immunicum AB disclose water use targets?
Sign up for free to unlockDoes Immunicum AB have careers partnerships with academic institutions?
Sign up for free to unlockDid Immunicum AB have a product recall in the last two years?
Sign up for free to unlockDoes Immunicum AB disclose incidents of discrimination?
Sign up for free to unlockDoes Immunicum AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Immunicum AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Immunicum AB disclose parental leave metrics?
Sign up for free to unlockDoes Immunicum AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Immunicum AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Immunicum AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes Immunicum AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Immunicum AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Immunicum AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Immunicum AB involved in embryonic stem cell research?
Sign up for free to unlockDoes Immunicum AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Immunicum AB disclose its waste policy?
Sign up for free to unlockDoes Immunicum AB report according to TCFD requirements?
Sign up for free to unlockDoes Immunicum AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Immunicum AB disclose energy use targets?
Sign up for free to unlockDoes Immunicum AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Immunicum AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Immunicum AB
These potential risks are based on the size, segment and geographies of the company.
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.